MedTrace Logo

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

NCT04590625 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2020-10-19

No results posted yet for this study

Summary

This monocentric, prospective, observational study will evaluate the safety and efficacy of apatinib in combination with albumin binds paclitaxel and carboplatin or cisplatinum as first-line treatment for stage II-IV epithelial ovarian cancer followed by apatinib maintenance therapy in routine clinical practice. Eligible patients will be followed for approximately 20 months.

Conditions

Interventions

DRUG

Apatinib Mesylate

apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd

DRUG

Abraxane

abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1

DRUG

Cis Platinum

cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1

DRUG

Carboplatin

carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1

Sponsors & Collaborators

  • Zhongshan Hospital Xiamen University

    lead OTHER

Principal Investigators

  • Li Xiao, Doctor · Zhongshan Hospital Xiamen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2022-10-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04590625 on ClinicalTrials.gov